Evidence map›Paper›PMID 30013564›Full record

ArticleFrontiers in immunology2018

No Overt Clinical Immunodeficiency Despite Immune Biological Abnormalities in Patients With Constitutional Mismatch Repair Deficiency.

Victoria K Tesch, Hanna IJspeert, Andrea Raicht, Daniel Rueda, Nerea Dominguez-Pinilla, Luis M Allende, Chrystelle Colas, Thorsten Rosenbaum, Denisa Ilencikova, Hagit N Baris and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Tandem Substitutions in Somatic Hypermutation.Frontiers in immunology · 2021
    Article
  9. Role of mismatch repair in aging.International journal of biological sciences · 2021
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 16 institutions in 9 countries.

Victoria K TeschResearch Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
Hanna IJspeertDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Andrea RaichtResearch Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
Daniel RuedaHereditary Cancer Laboratory, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
Nerea Dominguez-PinillaDepartment of Pediatric Hematology and Oncology, Virgen de la Salud Hospital, Toledo, Spain.
Luis M AllendeDepartment of Immunology, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
Chrystelle ColasGenetics Department, Curie Institute, Paris, France.
Thorsten RosenbaumDepartment of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.
Denisa IlencikovaDepartment of Pediatrics, Comenius University Bratislava, Bratislava, Slovakia.
Hagit N BarisThe Genetics Institute, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Michaela H M NathrathPediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany.
Manon SuerinkDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands.
Danuta Januszkiewicz-LewandowskaDepartment of Pediatric Oncology, Hematology and Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Iman RagabPediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Amedeo A AziziDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Soeren S WenzelDivision of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Johannes ZschockeDivision of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Wolfgang SchwingerResearch Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
Matthias KloorDepartment of Applied Tumor Biology, Institute of Pathology, Medical University Heidelberg, Heidelberg, Germany.
Claudia BlattmannDepartment of Hematology, Oncology, and Immunology, Olgahospital Stuttgart, Stuttgart, Germany.
Laurence BrugieresDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Mirjam van der BurgDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Katharina WimmerDivision of Human Genetics, Medical University Innsbruck, Innsbruck, Austria.
Markus G SeidelResearch Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
Medical University of Graz · ATInnsbruck Medical University · ATResearch Institute Hospital 12 de Octubre · ESErasmus MC · NLAin Shams University · EGComenius University Bratislava · SKHeidelberg University · DEInstitut Curie · FRInstitut Gustave Roussy · FRKlinikum Kassel · DELeiden University Medical Center · NLMedical University of Vienna · ATOlgahospital · DEPoznan University of Medical Sciences · PLSana Kliniken Duisburg · DETechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin class-switch recombination (CSR) and somatic hypermutations (SHMs) are prerequisites for antibody and immunoglobulin receptor maturation and adaptive immune diversity. The mismatch repair (MMR) machinery, consisting of homologs of MutSα, MutLα, and MutSβ (MSH2/MSH6, MLH1/PMS2, and MSH2/MSH3, respectively) and other proteins, is involved in CSR, primarily acting as a backup for nonhomologous end-joining repair of activation-induced cytidine deaminase-induced DNA mismatches and, furthermore, in addition to error-prone polymerases, in the repair of SHM-induced DNA breaks. A varying degree of antibody formation defect, from IgA or selective IgG subclass deficiency to common variable immunodeficiency and hyper-IgM syndrome, has been detected in a small number of patients with constitutional mismatch repair deficiency (CMMRD) due to biallelic loss-of-function mutations in one of the MMR genes (

Indexed as

class-switch recombinationDNA repair defecthyper-IgM syndromeIgA deficiencyIgG subclass deficiencymismatch repairprimary immunodeficiencysomatic hypermutation

Identifiers

PMID30013564
PMCPMC6036136
OpenAlexW2809219597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.